- « Previous
- Clinical Pharmacology
- Next »
Zofran Injection
Clinical Pharmacology
Zofran Injection
Adult Studies: Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients. ZOFRAN Injection (4 mg) I.V. given over 2 to 5 minutes was significantly more effective than placebo. The results of these studies are summarized in Table 8.
Table 8. Prevention of Postoperative Nausea and Vomiting in Adult Patients
| Ondansetron 4 mg I.V. |
Placebo | P Value | |
| Study 1 | |||
| Emetic episodes: | |||
| Number of patients | 136 | 139 | |
| Treatment response over 24-h postoperative period | |||
| 0 Emetic episodes | 103 (76%) | 64 (46%) | < 0.001 |
| 1 Emetic episode | 13 (10%) | 17 (12%) | |
| More than 1 emetic episode/rescued | 20 (15%) | 58 (42%) | |
| Nausea assessments: | |||
| Number of patients | 134 | 136 | |
| No nausea over 24-h postoperative period | 56 (42%) | 39 (29%) | |
| Study 2 | |||
| Emetic episodes: | |||
| Number of patients | 136 | 143 | |
| Treatment response over 24-h postoperative period | |||
| 0 Emetic episodes | 85 (63%) | 63 (44%) | 0.002 |
| 1 Emetic episode | 16 (12%) | 29 (20%) | |
| More than 1 emetic episode/rescued | 35 (26%) | 51 (36%) | |
| Nausea assessments: | |||
| Number of patients | 125 | 133 | |
| No nausea over 24-h postoperative period | 48 (38%) | 42 (32%) |
The study populations in Table 8 consisted mainly of females undergoing laparoscopic procedures.
In a placebo-controlled study conducted in 468 males undergoing outpatient procedures, a single 4-mg I.V. ondansetron dose prevented postoperative vomiting over a 24-hour study period in 79% of males receiving drug compared to 63% of males receiving placebo (P < 0.001).
Two other placebo-controlled studies were conducted in 2,792 patients undergoing major abdominal or gynecological surgeries to evaluate a single 4-mg or 8-mg I.V. ondansetron dose for prevention of postoperative nausea and vomiting over a 24-hour study period. At the 4-mg dosage, 59% of patients receiving ondansetron versus 45% receiving placebo in the first study (P < 0.001) and 41% of patients receiving ondansetron versus 30% receiving placebo in the second study (P=0.001) experienced no emetic episodes. No additional benefit was observed in patients who received I.V. ondansetron 8 mg compared to patients who received I.V. ondansetron 4 mg.
Generic Name: Ondansetron Hydrochloride Injection
- « Previous
- Clinical Pharmacology
- Next »
Cancer
Get the latest treatment options.
Cancer and Exercise
Resting to conserve energy may not be the best remedy for fatigue during radiation therapy. See more WebMD Videos »
